MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

01 Nov 2022 Evaluate

Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Glycopyrrolate Injection USP, 0.2 mg/1 mL and 0.4 mg/2 mL (0.2 mg/mL) Single-dose Vials and 1 mg/5 mL (0.2 mg/mL) and 4 mg/20 mL (0.2 mg/mL) Multiple-dose Vials. In this regard, the company has enclosed a press release.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1756.90
Dr. Reddys Labs. 1195.10
Cipla 1303.30
Lupin 1960.00
Zydus Lifesciences 1115.10
View more..